Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.

William J. Gradishar; Roberto Hegg; Seock‐Ah Im; In Hae Park; Sergei Tjulandin; Sarah Kenny; Séverine Sarp; Lisa Williams; Miguel Izquierdo; Stephen Johnston

doi:10.1200/jco.2017.35.15_suppl.1004

Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.

Identifier:nobleid.org/w1/20260515/7EBDB909

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/7EBDB909.svg?ark=w1%2F20260515%2F7EBDB909)](https://nobleid.org/work/w1/20260515/7EBDB909)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.

Identifier:nobleid.org/w1/20260515/7EBDB909

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/7EBDB909.svg?ark=w1%2F20260515%2F7EBDB909)](https://nobleid.org/work/w1/20260515/7EBDB909)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work